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Human CD23/Fc&RII is a 45 kDa type-11 membrane glycoprotein having two isoforms (a and b) that only differ in the structures of their 
intracytoplasmic tails. CD23/FczRII has been demonstrated to have multiple roles in the immune system such as regulation of lymphocyte growth 
and differentiation and IgE-mediated immune responses. Here, we found that the human B-cell line RPM18866, in addition to a and b transcripts, 
contained shorter transcripts (a’ and b’) that lack the entire third exon. These alternative transcripts were also detected in peripheral blood 
lymphocytes as well as other hematopoietic ell lines with CD23/Fc&RII. Because exon 3 encodes all of the transmembrane segment and the 
anchoring region of the cytoplasmic tail, it is suggested that a’ and b’ transcripts encode secretory forms of CD23/Fc&RII or they may function 
as regulatory transcripts involved in the control of CD23/Fc&RII expression. 
CD23/Fc&RII; Type-II cell surface receptor; C-type animal lectin; Alternative splicing; Soluble isoform 
1. INTRODUCTION 
Human CD23/Fc&RII is a low aflbity Fc receptor for 
IgE and plays various biological roles [ 11. It is expressed 
on @ positive B lymphocytes [2,3,4] as well as some T 
lymphocytes [5] and macrophages [6]. So far, two alter- 
native spliced human CD23/Fc&RII isoforms, namely a 
and b, have been demonstrated and their distributions 
and functions were intensively studied [7,8]. Type a and 
b CD23/Fc&RII differ in their cytoplasmic tails by the 
use of different initiating exons. Several different forms 
of soluble CD23/Fc&RII are cleaved from the extracel- 
lular domain [9] and some of them have been reported 
to be involved in regulation of immune-system func- 
tions such as proliferation of bone marrow-derived T 
cells [lo] and survival of germinal center B cells [l 11. 
Unlike other Fc receptors which belong to the immu- 
noglobulin superfamily, CD23/Fc&RII shows homol- 
ogy to C-type animal lectins such as the mannose bind- 
ing protein. Recently CD23/Fc&RII has also found to 
be a natural ligand of CD2llcomplement receptor 2 
WI. 
In the present studies we have determined that two 
additional transcripts of CD23/Fc&RII exist. These 
novel transcripts lack their entire third exons, regions 
which encode the anchoring and transmembrane do- 
mains [13], except for the new joint between exon two 
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and four, there are no changes in sequences of their 
amino acid reading frames. We analyzed the property 
of these transcripts in particular relation to formation 
of soluble receptor. 
2. MATERIALS AND METHODS 
Total RNA was purified from the human EBV-transformed B cell 
line RPM18866 and COS cells using guanidinium isothiocyanate and 
CsCl centrifugation. Single strand cDNA was synthesized using First- 
Strand cDNA Synthesis Kit (Pharmacia LKB Biotechnology, 
Uppsala, Sweden) following the manufacturer’s instructions. Oligonu- 
cleotide sequences of the primers used in the PCR are shown in Fig. 
1. PCR fragments were subcloned into pSP72 plasmid (Promega, 
Madison, WI) and sequenced using Sequenase (USB, Cleveland, OH) 
following the manufacturer’s instructions. The ribonuclease protec- 
tion assay was performed using RPA II kit (Ambion, Austin, TX) 
following the manufacturer’s instructions. Electroporation was per- 
formed using GenePulser (BioRad) under the condition of 0.4 kV, 125 
pF. Cell lysates were prepared by treating cells with solubilizing buffer 
containing 0.5% NP-40 for 30 min. Sandwich ELISA for the detection 
of CD23/Fc&RII was performed as previously described with a slight 
modification [5]. In this ELISA study, we used anti-CD2UFczRII 
mAb H107 and E70. Immunoblotting analysis was carried out by the 
method described previously [14]. 
3. RESULTS 
RT-PCR was performed to isolate human CD231 
FcERII N-terminal region cDNA using primers recog- 
nizing the 5’ untranslated region of either type a or b 
CD23/Fc&RII and a common extracellular region 
(Fig. 1). Unexpectedly, both primer pairs generated two 
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Fig. 1. Design of PCR primers for CD23/Fc&RII. Primer 1 is designed for exon 1, which is specific for type a CD23/Fc~R11. Primer 2 is for exon 
1 + 2 which is specific for type b CD23/FcsRII. Primer 3 is for exon 8, which is common to both CD23/FccRII isoforms. Hind111 sites (underlined) 
are artificially introduced in primer 1 and 2 at their 5’ end for further subcloning. The amplified type a and b CD23IFcsRII are expected to be 
the size of 579 and 498 base-pairs, respectively. 
bands, one of the expected size, and a second approxi- 
mately 100 bp smaller (Fig. 2). 
To determine the relationship between these two 
products, they were purified and subcloned in pSP72 
vector and sequenced. As can be seen in Fig. 3, the 
nucleotide sequences of the larger fragments were ex- 
actly the same as either type a or b CD23/FcsRII which 
have been already reported. The sequence of the smaller 
fragments were also identical with those of type a or b 
CD23/Fc&RII, except hat they do not contain the entire 
third exon. 
To further confirm the existence of these novel tran- 
scripts, we performed a ribonuclease protection assay 
using four riboprobes (Fig. 4). A significant amount of 
the predicted isoform was detected, but there were sev- 
eral additional bands whose origins were not clear. 
Because these data are reproducible, they may reflect 
additional transcripts or ribonuclease sensitive sites 
probably due to their secondary structures. 
To identify the characteristics of the putative proteins 
translated from these two novel transcripts, we con- 
structed both type a and b CD23/Fc&RII cDNA with- 
out the third exon, and designated these as type a’ and 
52 
type b’ CD23/FcsRII, respectively. COS-7 cells were 
transfected with these four types of CD23/Fc&RII 
cDNAs under the control of the SRa promoter. The 
ribonuclease protection assays using type a CD23/ 
FcERII riboprobes revealed that there were almost the 
same amount of introduced transcripts in these cells 
(Fig. 5). As for proteins, however, we only detected type 
a and b CD23/FcsRII using surface staining, im- 
munoblotting and enzyme-linked immunosorbent as- 
says (Fig. 6). We further introduced these cDNAs stably 
in a human lymphoid cell line, YT, but type a’ and b 
protein have not been detected so far, while type a and 
b are expressed successfully (data not shown). 
4. DISCUSSION 
We have identified skipping of exon 3 in both type a 
and b CD23/Fc&RII mRNA using RT-PCR and ribo- 
nuclease protection assays. In fact, it has been already 
noted by another group that the Sl-nuclease protection 
analysis of CD23/FcsRII showed unexplained bands 
[7], which are now considered to be derived from the 
novel isoforms presented here. Though the two splicing 
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Fig. 2. RT-PCR analysis of CD23/FcsRII transcripts. Total RNA was 
extracted from RPM18866 cells using GTC method and CsCl centrif- 
ugation. Complementary DNA was generated from 0.5 yg of the RNA 
and was used as templates for the PCR amplification (25 cycles). The 
products were analyzed with agarose gel electrophoresis. Lane 1 and 
lane 3 show the product using primers 1 and 3, primers 2 and 3, 
respectively. Bands 1 and 3 were expected CD23fFceRII fragments 
but bands 2 and 4 had not been expected. Lane 2 shows DNA marker 
(4X 174/H&&I digest). 
donor sites are different, both can use the same se- 
quence just before the third exon as acceptor. In our 
RT-PCR, we could not detect other types of splicing. 
Because exon 3 is 114 base pairs long, this deletion 
causes only one junctional amino acid change while 
preserving the following amino acid reading frame. Fur- 
ther preliminary RT-PCR analysis demonstrated these 
novel transcripts in peripheral blood lymphocytes and 
in other hematopoietic ell lines with CD23/Fct-RI1 and 
we are now investigating their quantitative changes 
under various conditions. We also detected skipping of 
the transmembrane segment in transcript of murine 
CD23/FaRII [ 151. These observations, together with 
the same findings with murine and human CD231 
FcERII, suggests that deletional splicing of exon 3 may 
have a biological importance rather than being a non- 
functional aberrant splicing. 
A considerable number of cell surface receptors such 
as neural cell adhesion molecule f16], growth hormone 
receptor 1171, interleukin-4 receptor I187 and fibroblast 
growth factor receptor [ 191 have been found to produce 
a soluble isofonn using alternative splicing. A common 
structural feature of those receptors is a signal peptide 
at their 5’ end and their N-terminus outside and C- 
terminus inside the cell. In those receptors, alternative 
splicing which introduces a stop codon just upstream of 
the transmembrane segment results in the deletion of 
the following amino acids without affecting the extracel- 
lular segment. It seems particularly important for those 
spliced products to preserve a signal sequence for their 
efficient expression of protein. On the contrary, in the 
case of reverse-oriented type-II cell surface receptors 
such as CD~~/FIXRII, introducing a stop codon up- 
stream of the transmembrane segment results in the loss 
of the entire extracellular segment, so this mechanism 
would not produce a soluble isoform. Instead, it is plau- 
sible that deletional splicing of the transmembrane-cod- 
ing exon(s), as we report here for human CD23IFceRI1, 
generates a soluble isoform, because this mechanism 
maintains the extracellular segment. However, as far as 
we know, such a mechanism has never been reported yet 
and this case probably is the first example. 
In addition, because one of the type-II transmem- 
brane proteins, invariant chain, was known to function 
in the cytoplasm as a transporter of MHC class II mol- 
ecules [20], it is also needed to see whether these novel 
CD23/Fc&RII isoforms are present intracellularly. 
Although the ribonuclease protection assay docu- 
ments that the a’ and b’ isoforms of CD23/Fc(sRII occur 
at the level of transcripts both in RPM18866 and in COS 
transfectants, immunoblotting and ELISA have been 
unsuccessful in detecting the exon 3 deleted CD231 
FceRII at the protein level. Althou~ we cannot com- 
pletely exclude the possibility of the protein expression 
type a’ 
gaccgcc&&3aggaaggtcaatattcag~ctgggacaccaca 
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exon2 ,I, exon4 
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A 
c 
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Fig. 3. Sequence of the PCR fragments. PCR products corresponding 
to the band 2 and band 4 in Fig. 2 were puritied from the gel and 
subcloned into pSP72 plasmids and sequenced. These sequence data 
showed absence of the entire third exon. This change did not affect 
the reading frame. We designated these new fragments as type a’ and 
b’ CD231FceRII isoforms, respectively. 
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Fig. 4. Ribonuclease protection assay on RPM18866. Total RNA (1Opg) prepared from RPM18866 was annealed to each single strand probe, which 
contained the sequence corresponding to the HindIII-Bg/II fragments of the type a, a’, b and b’ CD23/FcsRII cDNA and then digested with RNase 
A and RNase Tl. The size of protected bands were analyzed by polyacrylamide gel electrophoresis. The 222 base-pairs bands in lane a and lane 
b are derived from a’ and b’ RNA. The 389 base-pairs band in lane a’ and the 308 base-pairs band in lane b’ is derived from type a’ and b’ RNA, 
respectively. 
in different circumstances, a possible explanation for 
the discrepancy between mRNA and protein expression 
is that absence of an N-terminal signal peptide in C-type 
animal lectins such as CD23/Fc&RII, dictates that the 
substitutive hydrophobic transmembrane segment is 
necessary for post-translational translocation. 
Alternatively, the truncated a’ and b’ transcripts 
503 -+ 
336-4 
222 + 
167-’ 
might themselves be regulatory elements for expression 
of the full-length CD23/Fc&RII protein through a novel 
mechanism. It is probable that the skipping of exon 3 
converts full-length CD23/Fc&RII mRNA into unstable 
transcripts and this decreases the expression of full- 
length protein. A second possibility is that the full- 
length mRNA stabilities are negatively-correlated with 
those of truncated ones through competition for a com- 
mon degradation pathway. In either case exon 3 
deletional splicing would influence CD23/FcgRII ex- 
pression. 
It might be biologically real that CD23/FcsRII is 
c 
Fig. 5. Identification of introduced CD231FceRII isofonn transcripts. 
Type a, b, a’ and b’ CD23/Fc.?RII isoforms are introduced under the 
control of the SRa promoter. COS-7 cells were transfected with 10 pg 
of each expression vector by electroporation using GenePulser (Bio- 
Rad). After 48 hours, total RNA (10 pg) were prepared from these 
COS cells and ribonuclease protection assays were performed using 
type a CD23/FceRII riboprobes as in the legend of Fig. 4. The SO3 
base-pairs band in lane COS-a, the 222 and 167 base-pairs bands in 
lane COS-a’, the 336 base-pairs band in lane COS-b and the 222 
base-pairs band in lane COS-b’ are derived from the introduced CD23/ 
FcsRII isoform transcripts. The parental COS cell did not give these 
bands as shown in lane COS(-). These results were also confirmed by 
the ribonuclease protection assays using type a’, b and b’ riboprobes 
(data not shown). 
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Fig. 6. Protein expression of the introduced CD23/FcsRII isoforms. Type a, b, a’ and b’ CD23/FczRII isoforms arc introduced into COS-7 cells 
as described in the legend of Fig. 5. After 72 h, the cells were harvested and assayed for the level of CDZYFccRII protein expression. (a) Surface 
staining. The cells were stained with anti-CDZUFERII monoclonal antibody H107 and secondary FITC-labeled antibody and analyzed using 
flowcytometry. COS cells transfected with PBS (negative control) are also shown. (b,c) Sandwich ELISA. (b) Cell lysate or (c) Cell supcmatant 
were assayed with sandwich enzyme-linked immunosorbent assay using two different monoclonal antibodies against CD23/FczRII. The amount 
of CD23/Fc.sRII in cell lysate is indicated as ng/50 ,ug of total protein. Data from RPM18866 and PBS transfected COS-7 cells are also shown as 
positive and negative controls. (d) Immunoblotting analysis. Lysates of COS cells and RPM18866 solubilized in 0.5% Nonidet P-40 were 
electrophorased on a 15% polyacrylamide gel under nonreduced conditions. After electro-transfer to a polyvinylidene difluoride (PVDF) membrane 
(Millipore, Bedford, MA), the membrane was blocked with 2% BSA, and incubated with mAb H107. Horseradish peroxidase labelled anti-mouse 
IgG was used as the secondary antibody. The bands reactive with antibodies were visualized by horseradish peroxidase-ECL method (Amersham, 
Buckinghamshire, UK). Though both type a and b CD23/FceRII were clearly detected, type a’ and b’ could not be found with all these methods. 
regulated through multiple mechanisms including alter- 
native mRNA splicing as well as proteolytic cleavage of 
extracellular portion of intact surface molecule. Further 
studies are needed to investigate whether co-expression 
of the alternatively spliced CD23/Fc&RII alters the ac- 
tivity or function of the full-length receptor. 
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